Primary Series 1 Month mRNA ■ non-mRNA ■ Multiple Study Country VE (95% CI) Design Andrews et al., 2021 UK ΤN 0.84 (0.83, 0.86) H TN H Patalon et al., 2021 Israel 0.85 (0.83, 0.86) С 0.67 (0.65, 0.69) Lin et al., 2022 (Sep-Nov '21) USA \vdash Andrews et al., 2022 (age 19-49) UK TN 0.83 (0.82, 0.84) Andrews et al., 2022 (age 50+) 0.86 (0.85, 0.86) UK ΤN Patalon et al., 2022 0.59 (0.55, 0.64) MTN Israel USA Florea et al., 2022 0.67 (0.66, 0.68) MC MC Monge et al., 2022 Spain 0.51 (0.50, 0.52) Ranzani et al., 2022 0.54 (0.53, 0.54) Brazil MTN С 0.41 (0.39, 0.44) \vdash Laake et al., 2022 Norway С 0.52 (0.49, 0.54) Lin et al., 2022 (Jan-Jun '22) USA \vdash Chemaitelly et al., 2022 MC 0.57 (0.56, 0.58) Qatar 0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)

2 Months

Study	Country	Design		VE (95% CI)
Patalon et al., 2021	Israel	TN		0.86 (0.85, 0.87)
Lin et al., 2022 (Sep-Nov '21)	USA	С	 ■ 	0.48 (0.47, 0.49)
Andrews et al., 2022 (age 19-49)	UK	TN	Hel	0.78 (0.76, 0.79)
Andrews et al., 2022 (age 50+)	UK	TN	·	0.82 (0.81, 0.83)
Hulme et al., 2022	UK	MC	Heat	0.53 (0.52, 0.54)
Patalon et al., 2022	Israel	MTN	⊢ •I	0.43 (0.38, 0.48)
Florea et al., 2022	USA	MC	H el	0.54 (0.52, 0.56)
Ranzani et al., 2022	Brazil	MTN	■	0.34 (0.33, 0.35)
Stirrup et al., 2022	UK	С	├──	0.72 (0.62, 0.80)
Ng et al., 2022	Singapore	С	H el	0.32 (0.30, 0.33)
Ng et al., 2022	Singapore	С	├- ■─1	0.07 (0.03, 0.12)
Gonzalez et al., 2022	Argentina	MTN	H■	0.19 (0.17, 0.20)
Laake et al., 2022	Norway	С	H ≡ H	0.37 (0.35, 0.39)
Lind et al., 2022	USA	TN		0.55 (0.48, 0.61)
Lin et al., 2022 (Jan-Jun '22)	USA	С	⊢ ■-I	0.36 (0.34, 0.39)
			0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)	

3 Months

Study	Country	Design				VE (95% CI)
Lin et al., 2022 (Sep-Nov '21)	USA	С		=		0.39 (0.38, 0.40)
Andrews et al., 2022 (age 19-49)	UK	TN		⊢		0.78 (0.66, 0.86)
Andrews et al., 2022 (age 50+)	UK	TN				0.82 (0.71, 0.89)
Patalon et al., 2022	Israel	MTN		⊢■⊣		0.29 (0.26, 0.32)
Florea et al., 2022	USA	MC		├──		0.30 (0.21, 0.39)
Ranzani et al., 2022	Brazil	MTN		H		0.25 (0.24, 0.25)
Stirrup et al., 2022	UK	С		⊢		0.69 (0.60, 0.76)
Gonzalez et al., 2022	Argentina	MTN	 ■ 			-0.04 (-0.06, -0.01)
Laake et al., 2022	Norway	С		I ■ I		0.33 (0.30, 0.35)
Lind et al., 2022	USA	TN				0.44 (0.34, 0.53)
Lin et al., 2022 (Jan-Jun '22)	USA	С		H ■ H		0.16 (0.14, 0.19)
			0	0.25 0.5 Vaccine Effectiveness (V	0.75 1	